Optimization of GPR40 Agonists for Type 2 Diabetes

[Image: see text] GPR40 (FFA1 and FFAR1) has gained significant interest as a target for the treatment of type 2 diabetes. TAK-875 (1), a GPR40 agonist, lowered hemoglobin A1c (HbA1c) and lowered both postprandial and fasting blood glucose levels in type 2 diabetic patients in phase II clinical tria...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Liu, Jiwen (Jim), Wang, Yingcai, Ma, Zhihua, Schmitt, Mike, Zhu, Liusheng, Brown, Sean P., Dransfield, Paul J., Sun, Ying, Sharma, Rajiv, Guo, Qi, Zhuang, Run, Zhang, Jane, Luo, Jian, Tonn, George R., Wong, Simon, Swaminath, Gayathri, Medina, Julio C., Lin, Daniel C.-H., Houze, Jonathan B.
格式: Artigo
語言:Inglês
出版: American Chemical Society 2014
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4027784/
https://ncbi.nlm.nih.gov/pubmed/24900872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml400501x
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍